Literature DB >> 23455757

Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses.

Shao-Ming Wang1, Danny Colombara, Ju-Fang Shi, Fang-Hui Zhao, Jing Li, Feng Chen, Wen Chen, Shu-Min Li, Xun Zhang, Qin-Jing Pan, Jerome L Belinson, Jennifer S Smith, You-Lin Qiao.   

Abstract

OBJECTIVE: This study aims to evaluate human papillomavirus (HPV) viral loads as a biomarker for triage into colposcopy and cervical intraepithelial neoplasia grade 2 (CIN2) therapy to reduce the colposcopy referral rate and CIN2 overtreatment in low-resource settings.
METHODS: In 1999, 1997 women aged 35 to 45 years in Shanxi, China, received 6 cervical screenings with pathological confirmation. In 2005, 1461 histologically normal women, 99 with CIN grade 1 (CIN1), and 30 with CIN2 or worse (CIN2+) were rescreened in a follow-up study. Human papillomavirus was detected by Hybrid Capture 2. Viral load, estimated by the ratio of relative light units to standard positive control (RLU/PC), was categorized into 4 groups: negative (<1.0), low (≥1.0, <10.0), moderate (≥10.0, <100.0), and high (≥100.0). We estimated the cumulative incidence of CIN2+ by viral load subgroups and calculated adjusted hazard ratios for CIN2+ using Cox proportional hazards regression.
RESULTS: Cumulative incidence of CIN2+ increased with baseline HPV viral loads among normal women and women with CIN1 at baseline (P(-trend) < 0.001). Repeat moderate-high viral load was associated with the highest risk for CIN2+ (adjusted hazard ratio, 188.8; 95% confidence interval, 41.2-864.1). Raising the ratio of relative light units to standard positive control cutoff from 1.0 to 10.0 for colposcopy greatly reduced the referral rate from 18.1% to 12.9%. It also increased the specificity (84.8% vs 90.4%), the positive predictive value (22.5% vs 28.9%), and the positive likelihood ratio (6.4 vs 8.9), yet with loss of sensitivity by 12% (97.6% vs 85.7%). Among women with CIN2 at baseline, 56% regressed to normal, 24% regressed to CIN1, 4% remained CIN2, and 16% progressed to CIN grade 3 or worse.
CONCLUSIONS: Locales using HPV testing as the primary screening method and lacking high-quality cytology-based screening should consider viral load as an alternative to colposcopy triage for women older than 35 years. Viral loads may also predict CIN2 progression until additional biomarkers become available.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455757      PMCID: PMC3636161          DOI: 10.1097/IGC.0b013e318286a95d

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  23 in total

1.  Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

Authors:  Fang-Hui Zhao; Margaret Jane Lin; Feng Chen; Shang-Ying Hu; Rong Zhang; Jerome L Belinson; John W Sellors; Silvia Franceschi; You-Lin Qiao; Philip E Castle
Journal:  Lancet Oncol       Date:  2010-11-11       Impact factor: 41.316

2.  The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3.

Authors:  Irene Tveiterås Ovestad; Einar Gudlaugsson; Ivar Skaland; Anais Malpica; Ane Cecilie Munk; Emiel A M Janssen; Jan P Baak
Journal:  J Clin Pathol       Date:  2011-04       Impact factor: 3.411

Review 3.  EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Authors:  Marc Arbyn; Silvia de Sanjosé; Mona Saraiya; Mario Sideri; Joel Palefsky; Charles Lacey; Maura Gillison; Laia Bruni; Guglielmo Ronco; Nicolas Wentzensen; Julia Brotherton; You-Lin Qiao; Lynnette Denny; Jacob Bornstein; Laurent Abramowitz; Anna Giuliano; Massimo Tommasino; Joseph Monsonego
Journal:  Int J Cancer       Date:  2012-07-02       Impact factor: 7.396

Review 4.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.

Authors:  Teresa M Darragh; Terence J Colgan; J Thomas Cox; Debra S Heller; Michael R Henry; Ronald D Luff; Timothy McCalmont; Ritu Nayar; Joel M Palefsky; Mark H Stoler; Edward J Wilkinson; Richard J Zaino; David C Wilbur
Journal:  J Low Genit Tract Dis       Date:  2012-07       Impact factor: 1.925

5.  Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer.

Authors:  Chang Sun; Laura L Reimers; Robert D Burk
Journal:  Gynecol Oncol       Date:  2011-04       Impact factor: 5.482

Review 6.  The 2001 Bethesda System: terminology for reporting results of cervical cytology.

Authors:  Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

7.  Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

Authors:  J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

8.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

9.  Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study.

Authors:  Christothea Constandinou-Williams; Stuart I Collins; Sally Roberts; Lawrence S Young; Ciaran B J Woodman; Paul G Murray
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 10.  Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review.

Authors:  Matejka Rebolj; Jesper Bonde; Sisse Helle Njor; Elsebeth Lynge
Journal:  BMJ       Date:  2011-05-23
View more
  14 in total

1.  Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.

Authors:  Long Fu Xi; Mark Schiffman; James P Hughes; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-17       Impact factor: 4.254

Review 2.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China.

Authors:  Margaret Z Wang; Rui-Mei Feng; Shaoming Wang; Xian-Zhi Duan; Dong Li; Xun Zhang; Rong Mu; Youlin Qiao; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

4.  Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections.

Authors:  Christophe E Depuydt; Jef Jonckheere; Mario Berth; Geert M Salembier; Annie J Vereecken; Johannes J Bogers
Journal:  Cancer Med       Date:  2015-05-20       Impact factor: 4.452

5.  Human papillomavirus type 18 infection in a female renal allograft recipient: a case report.

Authors:  Maksims Cistjakovs; Alina Sultanova; Olga Jermakova; Svetlana Chapenko; Baiba Lesina-Korne; Rafail Rozental; Dace Razeberga; Modra Murovska; Ieva Ziedina
Journal:  J Med Case Rep       Date:  2016-11-09

6.  Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.

Authors:  Inger Gustavsson; Riina Aarnio; Malin Berggrund; Julia Hedlund-Lindberg; Ann-Sofi Strand; Karin Sanner; Ingrid Wikström; Stefan Enroth; Matts Olovsson; Ulf Gyllensten
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

7.  Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study.

Authors:  Li Dong; Li Zhang; Shang-Ying Hu; Rui-Mei Feng; Xue-Lian Zhao; Qian Zhang; Qin-Jing Pan; Xun Zhang; You-Lin Qiao; Fang-Hui Zhao
Journal:  Clin Epigenetics       Date:  2020-05-07       Impact factor: 6.551

8.  Role of FAM19A4/miR124-2 methylation analysis in predicting regression or non-regression of CIN2/3 lesions: a protocol of an observational longitudinal cohort study.

Authors:  Wieke W Kremer; Johannes Berkhof; Maaike Cg Bleeker; Daniëlle Am Heideman; Nienke E van Trommel; Marchien W van Baal; Harold R Verhoeve; Chris Jlm Meijer; Gemma G Kenter
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

Review 9.  The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa.

Authors:  Anna-Lise Williamson
Journal:  J Clin Med       Date:  2015-04-02       Impact factor: 4.241

Review 10.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.

Authors:  Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala
Journal:  BMJ       Date:  2018-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.